BioAge Labs (NASDAQ:BIOA) Releases Earnings Results

BioAge Labs (NASDAQ:BIOA) announced its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.05), FiscalAI reports. The business had revenue of $0.30 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%.

BioAge Labs Price Performance

Shares of BioAge Labs stock traded down $0.20 on Friday, reaching $5.34. The company had a trading volume of 683,456 shares, compared to its average volume of 921,440. The firm has a market cap of $245.11 million, a price-to-earnings ratio of -2.09 and a beta of 1.19. The firm’s 50-day moving average price is $6.99 and its two-hundred day moving average price is $15.48. BioAge Labs has a 1 year low of $4.81 and a 1 year high of $25.95.

Wall Street Analyst Weigh In

BIOA has been the subject of several research analyst reports. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of BioAge Labs in a report on Tuesday, September 8th. UBS Group began coverage on shares of BioAge Labs in a research note on Sunday, October 11th. They issued a “neutral” rating and a $8.00 target price on the stock. Roth Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Wednesday, September 9th. Weiss Ratings raised BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. Finally, Wall Street Zen cut BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Institutional Investors Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in BioAge Labs during the 2nd quarter valued at about $69,831,000. Jupiter Topco LLC purchased a new stake in BioAge Labs during the second quarter valued at approximately $52,597,000. Janus Henderson Group PLC grew its stake in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP increased its holdings in shares of BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in BioAge Labs during the 2nd quarter valued at approximately $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.